Skip to content

Revvity RVTY Stock-Based Comp

Stock-Based Comp at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Illumina logo
IlluminaILMN
IQVIA logo
IQVIAIQV
Veeva Systems logo
Veeva SystemsVEEV
Roivant Sciences logo
Roivant SciencesROIV
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's stock-based comp?
Revvity (RVTY) reported stock-based comp of $8.72M in Q1 2026.
How has Revvity's stock-based comp changed year-over-year?
Revvity's stock-based comp increased by 12.7% year-over-year, from $7.73M to $8.72M.
What is the long-term trend for Revvity's stock-based comp?
Over 3 years (2021 to 2024), Revvity's stock-based comp has grown at a 8.4% compound annual growth rate (CAGR), from $29.68M to $37.81M.